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Objectives. We attempted to determine the relation between 
estrogen replacement herapy and the rate of restenosis after 
coronary angioplasty and atherectomy. 
Background. Although estrogen replacement therapy in women 
has been associated with a reduction in cardiovascular events and 
improvement in endothelial function, no study has examined 
whether estrogen reduces restenosis rates after percutaneous 
coronary interventions. 
Methods. A total of 204 women enrolled in the Coronary 
Angioplasty Versus Excisional Atherectomy Trial with angio- 
graphic follow-up were contacted, and their menopausal and 
estrogen replacement status was determined. Late loss in minimal 
lumen diameter, late loss index, minimal lumen diameter, rate of 
restenosis >50% and actual percent of stenosis were compared in 
estrogen users and nonusers by quantitative coronary angiogra- 
phy at 6-month follow-up. 
Results. Late loss in minimal lumen diameter was significantly 
less in women using estrogen than in nonusers (-0.13 vs. 
-0.46 mm, p = 0.01). A regression analysis of the determinants of 
late loss in minimal lumen diameter revealed that estrogen use 
was the single most important predictor of subsequent late loss 
(F = 13.38, p = 0.0006). Formal testing revealed a highly 
significant interaction between the use of estrogen and interven- 
tion (angioplasty or atherectomy). Women undergoing atherec- 
tomy who received estrogen had a significantly lower late loss 
index (0.06 vs. -0.63, p = 0.002), less late loss (0.06 vs. -0.61 ram, 
p = 0.0006), larger minimal lumen diameter (p = 0.044) and 
lower resteuosis rates (p = 0.038 for >50% stenosis) than those 
not using estrogen. In contrast, estrogen had minimal effects on 
restenosis end points after angioplasty. 
Conclusions. This study demonstrates the potential for estro- 
gen replacement herapy to reduce angiographic measures of 
restenosis in postmenopausal women after coronary intervention, 
particularly in those undergoing atherectomy. 
(JAm CoU Cardiol 1996;28:1111-8) 
Restenosis remains amajor limitation to the long-term benefit 
of percutaneous transluminal coronary angioplasty and direc- 
tional coronary atherectomy. Several clinical studies (1-4) 
have reported the rate of angiographically defined late resten- 
osis after angioplasty to be between 30% and 50%. Despite 
multiple clinical trials evaluating numerous pharmacologic 
agents (5-12), few drugs to date have shown any potential to 
significantly reduce the rate of restenosis. However, none of 
these previous tudies examined the value of estrogen replace- 
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ment therapy in decreasing the rate of restenosis n selected 
patients. 
Extensive observational data exist detailing an association 
between estrogen replacement therapy and a reduction in 
cardiovascular disease in postmenopausal women. Primarily 
epidemiologic studies have demonstrated a 50% reduction in 
the relative risk of cardiovascular events in postmenopausal 
women taking estrogen compared with those not receiving 
estrogen (13,14). In addition, recent studies (15-27) suggest 
that estrogen may reduce the progression of existing coronary 
artery disease in postmenopausal women, favorably modulate 
the vascular biology of atherosclerotic coronary arteries and 
limit the proliferation of vascular smooth muscle after endo- 
thelial injury. 
Given these potential favorable effects of estrogen on 
coronary vascular biology, we hypothesized that estrogen re- 
placement therapy in postmenopausal women would reduce 
angiographic measures of restenosis and improve functional 
status and clinical outcomes after percutaneous coronary in- 
terventions. To test this hypothesis, we examined the impact of 
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estrogen on restenosis in the Coronary Angioplasty Versus 
Excisional Atherectomy Trial (CAVEAT I). 
Methods 
Study patients. A detailed escription of the trial has been 
published previously (28). Between August 1991 and April 
1992, 275 women who had given written informed consent in 
the United States and Europe were randomized to either 
angioplasty or atherectomy at 35 sites participating in 
CAVEAT I. Eligibility criteria included the presence of symp- 
tomatic ischemic heart disease amenable to treatment with 
either angioplasty or atherectomy, diseased native coronary 
vessels with no previous coronary interventions, and ->60% 
stenosis on visual assessment. Patients with multivessel disease 
were eligible, but a single target vessel suitable for either 
angioplasty or atherectomy was specified before coronary 
intervention. Although the study protocol considered a resid- 
ual stenosis of <20% optimal, a reduction of lesions to ---50% 
diameter stenosis was considered a successful procedure. 
For the current study, we included only the 254 women 
randomized within 32 hospitals participating in CAVEAT I 
within the United States in order to ensure a consistent 
method of data collection and subsequent verification. 
Angiographic analysis. As part of CAVEAT I, the proce- 
dural details of angioplasty and atherectomy and the results of 
cardiac catheterization were collected prospectively. The 
cineangiograms were quantitatively analyzed at the Cleveland 
Clinic Foundation by technicians who had no knowledge of 
intervention assignments oroutcome data (28). When multiple 
views of the target lesion were available, the most severe 
hemiaxial view of the stenosis without foreshortening was 
selected for analysis. End-diastolic ine frames from orthogo- 
nal views were digitized with a cine-video converter and a 
computer-assisted ge detection algorithm (29). 
A total of 204 (80%) of 254 eligible women in CAVEAT I 
had angiographic follow-up within 6 months. If a patient 
underwent repeat catheterization before the scheduled proce- 
dure because of a change in clinical status, that angiogram was 
used to obtain follow-up data. The reasons for failure to obtain 
angiographic follow-up included refusal to undergo repeat 
catheterization (27 patients), coronary artery bypass urgery 
(n = 10), death (n = 5), intercurrent illness (n = 2), lost to 
follow-up (n = 5) and withdrawal from the study (n = 1). Of 
the 50 women without angiographic follow-up, 6 were using 
estrogen replacement therapy. Of these six, three subsequently 
had coronary artery bypass urgery and all three refused to 
undergo repeat catheterization. 
End points. The primary angiographic end point for the 
current study was prospectively defined as the mean difference 
in minimal umen diameter between the 6-month angiogram 
and the postprocedure angiogram (late loss) as determined by 
quantitative angiography. This end point has been used in 
several previous angiographic restenosis trials (4). Secondary 
angiographic end points included 1) the late loss index (late 
loss divided by immediate gain in minimal lumen diameter), 2) 
minimal umen diameter at follow-up, 3) dichotomous rate of 
restenosis (>50% stenosis), and 4) actual percent stenosis at 
6-month follow-up. 
The clinical end points collected at 1 year included all-cause 
mortality, myocardial infarction, coronary artery bypass sur- 
gery, repeat cardiac atheterization a d exertional angina class 
(defined by Canadian Cardiovascular Society class). A com- 
posite 1-year clinical end point was also defined as death, 
myocardial infarction, coronary artery bypass surgery and 
nonsurgical coronary intervention i the target artery. 
Determination f estrogen replacement use. A total of 246 
(97%) of 254 women previously enrolled in CAVEAT I from 
the United States were contacted between March and May 
1995. Menopausal status and estrogen replacement s atus at 
the time of randomization and at the 6-month and 1-year 
follow-up were collected by structured telephone interview by 
one investigator who had no knowledge of outcome data. Of 
254 women, 7 could not be contacted by telephone but 
subsequently responded to a mailed questionnaire. A total of 
eight women could not be contacted by telephone or mailed 
questionnaire (six of the eight died after randomization and 
two were lost to follow-up). For the six women who died after 
randomization, both medical record review and physician 
contact were used to determine strogen replacement status. 
Nine women were determined to be premenopausal at the 
time of percutaneous coronary intervention by interview or 
questionnaire and were removed from all subsequent analyses. 
For the purpose of the study, positive estrogen replacement 
status was specified as unopposed estrogen or combined 
estrogen/progestin regimens initiated before the time of initial 
coronary intervention and used continuously through both 
6-month and 1-year follow-up. Any patient who discontinued 
estrogen replacement therapy before angiographic or 1-year 
follow-up was considered to be in the nonestrogen replace- 
ment group (four patients). Positive estrogen replacement 
status was verified for all respondents by a combination of 
medical record review and prescribing physician contact. 
Statistical analysis. Baseline characteristics of the estro- 
gen replacement and the nonestrogen replacement groups are 
presented as medians with interquartile ranges for continuous 
variables and percentages for discrete variables. Selected base- 
line characteristics and clinical and angiographic outcomes 
were compared between groups by using the Wilcoxon rank- 
sum test for continuous variables and the Mantel-Haenzel 
chi-square test or Fisher exact test, where appropriate, for 
discrete variables. Kaplan-Meier curves were used to compare 
the probability of clinical outcomes for the 1-year follow-up 
period by estrogen replacement s atus. The two study groups 
were compared with respect o clinical outcomes and compos- 
ite end point at 1 year with use of the log rank test. The Fisher 
exact est was also used to evaluate angina class at 1 year for 
both groups. Because patients underwent 1-year follow-up at 
varying times, the angina class used as the 1-year follow-up 
value was obtained between 8 and 16 months after random- 
ization. All tests of significance were two-tailed. 
Multiple linear egression was used to assess the association 
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between late loss in minimal umen diameter at follow-up and 
estrogen use after adjusting for multiple baseline clinical 
factors known to affect he rate of restenosis. The independent 
variables considered in this model included patient age, dia- 
betes mellitus, current smoking, hypertension, high density 
lipoprotein level, unstable angina, vessel diameter, preproce- 
dure minimal umen diameter, presence of a lesion in the left 
anterior descending coronary artery, type of coronary inter- 
vention (angioplasty or atherectomy), and use or nonuse of 
estrogen replacement. To investigate whether the effect of 
estrogen use on restenosis differed between patients who 
underwent directional coronary atherectomy versus those who 
had coronary angioplasty, we included a formal test for inter- 
action between coronary intervention and estrogen use. As this 
interaction term (coronary intervention × estrogen use) was 
significant (p = 0.005), we stratified our angiographic out- 
comes by the type of coronary intervention received. In 
addition, unadjusted univariable analyses of the independent 
variables considered in the multivariable model were used to 
evaluate correlates of late loss in minimal umen diameter. 
Resu l ts  
Of 243 women, 47 (19%) were using continuous unopposed 
estrogen or combined estrogen/progestin regimens before cor- 
onary intervention through the time of l-year clinical follow- 
up. Thirty-eight (81%) of these women were taking unopposed 
conjugated equine strogen (32 patients), estradiol (n = 4) or 
estrone (n -- 2). Nine patients reported use of combined 
estrogen/progestin regimens. No woman reported initiating 
estrogen replacement therapy after coronary intervention or 
6-month angiographie follow-up. 
Characteristics of the patients. The baseline characteris- 
tics of the estrogen replacement users and nonusers are shown 
in Table 1. Women receiving estrogen replacement therapy 
were significantly younger, more likely to be smokers and more 
often had a positive family history of coronary artery disease. 
In addition, women using estrogen had significantly higher 
levels of high density lipoprotein and lower baseline rates of 
classes III and IV angina before coronary intervention. The 
two groups were similar with respect o factors associated with 
an increased risk of restenosis, including unstable angina and 
lesion location in the left anterior descending artery. 
Immediate angiographic outcomes. The baseline anglo- 
graphic data and immediate interventional outcomes in estro- 
gen users and nonusers are displayed in Table 2. Percent 
stenosis before and after intervention was similar between 
estrogen users and nonusers. Women using estrogen replace- 
ment had smaller minimal umen diameters before and after 
intervention (p = 0.05 and 0.055, respectively). However, the 
immediate gain for both estrogen users and nonusers varied 
little (0.93 vs. 0.97 mm, p = 0.71). Likewise, immediate success 
rate (defined as -<50% stenosis by quantitative angiography) 
was high in both estrogen users and nonusers (89% vs. 89%, 
p = 1,0). 
Table 1. Baseline Clinical and Angiographic Characteristics 
Estrogen Estrogen 
Users Nonusers p 
(n -- 47) (n = 196) Value 
Age (yr) 60 (52, 67) 64 (57, 71) 0.003 
Diabetes 25% 33% 0.31 
Current smoker 30% 17% 0.054 
Hypertension 62% 63% 0.89 
Cholesterol (mg/dl) 233 (209, 261) 226 (199, 253) 0.34 
High density lipoprotein 54 (4l, 60) 39 (32, 50) 0.002 
(m~'dl) 
Family history of CAD 61% 38% 0.005 
Prior history of myocardial 28% 41% 0.084 
infarction 
Comorbid disease* 38% 41% 0.70 
CCS angina class III or IV 57% 73% 0.032 
Unstable angina 81% 84% 0.64 
Target vessel = LAD 54% 51% 0.71 
*Comorbid disease includes renal insufficiency (creatinine >1.5 mg/dl), 
malignancy, chronic lung disease, rheumatologic disease, alcohol abuse, depres- 
sion, physician-diagnosed obesity, gastrointestinal bleeding and cirrhosis. Data 
presented are median value (25th, 75th percentile) or percent of patient group. 
CAD - coronary, artery disease; CCS - Canadian Cardiovascular Society; 
LAD left anterior descending coronary, artery. 
Six-month follow-up. The angiographic follow-up data are 
displayed in Table 3 and Figure 1. The primary end point, the 
median late loss in minimal umen diameter, was significantly 
lower in women using estrogen than in nonusers (-0.13 vs. 
-0.46 mm, p = 0.01). In fact, univariable analysis of potential 
risk factors of restenosis revealed that estrogen use was the 
strongest predictor of late loss in minimal lumen diameter 
(F = 10.56, p = 0.001). In a multivariable analysis, the 
reduction in late loss remained significant after adjusting for 
potential risk factors for restenosis, including age, diabetes, 
current smoking, hypertension, high density lipoprotein level, 
unstable angina, vessel diameter, preprocedure minimal lumen 
diameter, presence of a lesion in the left anterior descending 
artery and type of coronary intervention (angioplasty or 
atherectomy). Multivariable regression analysis also found that 
estrogen use was the single most important predictor of 
subsequent late loss (F = 13.38, p = 0.0006). The only other 
Table 2. Immediate Angiographic Outcomes 
Estrogen Estrogen 
Users Nonusers p 
(n = 47) (n - 196) Value 
Preprocedure stenosis (%) 73 (63, 79) 72 (62, 78) 0.38 
Postprocedure stenosis (%) 36 (29, 43) 35 (29, 45) 0.81 
Preprocedure MLD (ram) 0.67 (0.48, 1.03) 0.82 (0.62, 1.06) 0.05 
Postprocedure MLD (ram) 1.64 (1.42, 1.78) 1.75 (1.48, 2.06) 0.055 
Acute gain (ram)* 0.93 (0.56, 1.19) 0.97 (0.62, 1.24) 0.71 
Success rater 89% 89% 1.0 
*Defined as postprocedure minimal umen diameter minus preprocedure 
minimal lumen diameter, iRate of reduction of stenosis to <-50% as assessed by 
quantitative angiography. Data presented are median value (25th, 75th percen- 
tile) or percent of patient group. MLD = minimal umen diameter. 
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Table 3. Angiographic Outcomes at Six-Month Follow-Up 
Estrogen Users Estrogen Nonusers p 
(n = 41) (n = 163) Value 
Late loss (mm)* -0.13 (-0.78, 0.12) -0.46 (-0.80, 0,12) 0.01 
Late loss indexi -0.136 (0.71, 0.17) -0.52 (-0.92, -0.18) 0.005 
Minimal lumen 1.37 (0.85, 1.80) 1.24 (0.89, 1.68) 0.55 
diameter (ram) 
Rate of restenosist: 41% 50% 0.26 
Percent stenosis 48 (31, 60) 55 (38, 67) 0.18 
(%)§ 
Vessel caliber (mm) 2.5 (2.2, 3.0) 2.7 (2.4, 3.0) 0.03 
*Defined as 6-month follow-up minimal umen diameter minus postproce- 
dure minimal lumen diameter. ]Late loss divided by acute gain in minimal lumen 
diameter. 5>50% stenosis after an initially successful procedure. §Actual 
percent stenosis. Data presented are median value (25th, 75th percentile) or 
percent of patient group. 
clinical factors found to significantly affect late loss were the 
intervention (F = 8.08, p -- 0.005) and the interaction between 
the intervention and estrogen use (F -- 7.22, p = 0.008). 
Although the late loss index varied significantly between 
estrogen users and nonusers (-0.126 vs. -0.522, p = 0.005), 
no significant differences existed when the other secondary 
angiographic end points were analyzed. However, similar 
trends toward improved outcomes were noted among estrogen 
users (Table 3). Despite having smaller lumen diameters 
before and after intervention, women using estrogen had a 
slightly larger median minimal lumen diameter at 6-month 
follow-up than did nonusers (1.37 vs. 1.24 ram, p -- 0.55). In 
addition, estrogen users tended to have a lower restenosis rate 
(>50% stenosis) than did nonusers when the dichotomous end 
point was used (41% vs. 50%, p = 0.26). 
As noted before, a predetermined analysis included inves- 
tigating whether the effects of estrogen replacement therapy 
on angiographic restenosis varied between those who under- 
went atherectomy and those treated with conventional ngio- 
plasty. The testing for an interaction between coronary inter- 
vention and estrogen replacement use confirmed the existence 
of this differential effect. Therefore Table 4 and Figures 2 and 
3 display angiographic outcomes by coronary intervention and 
estrogen status. The median late loss in estrogen users under- 
going atherectomy was 0.06 mm compared with -0.61 mm in 
nonusers (p = 0.0006). Likewise, the late loss index varied 
significantly between estrogen users and nonusers treated with 
atherectomy (0.06 vs. -0.63, p = 0.002). The median minimal 
lumen diameter in estrogen users undergoing atherectomy was 
larger than in nonusers (1.63 vs. 1.15 mm, p = 0.044), and the 
dichotomous restenosis rate (>50% stenosis) in estrogen users 
undergoing atherectomy was 27% compared with 57% in 
nonusers (p = 0.038). Little difference in minimal lumen 
diameter existed between estrogen users and nonusers who 
underwent angioplasty (1.26 vs. 1.32 mm, p = 0.34). Similarly, 
the dichotomous restenosis rates were not significantly differ- 
ent between estrogen users and nonusers who received angio- 
plasty. 
Clinical outcomes. The clinical events and cumulative clin- 
ical outcome at 1-year follow-up are shown in Table 5. Six 
patients (3%) in the nonestrogen replacement group died 
within 365 days of coronary intervention. No deaths occurred 
in the estrogen replacement group. The rates of myocardial 
infarction, coronary artery bypass urgery and need for coro- 
nary intervention were slightly lower in estrogen users than in 
nonusers. The composite clinical end point (death, myocardial 
infarction, coronary artery bypass surgery and nonsurgical 
coronary intervention i  the target artery) was similar between 
estrogen users and nonusers (15 events [31.9%] vs. 71 [35.5%], 
p = 0.75). However, the number of patients who were classi- 
fied as having class II, III or IV angina at follow-up demon- 
strated a trend toward less severe angina in estrogen users (5 
patients [10.6%] vs. 31 [21.3%], p = 0.29). 
Discussion 
Restenosis remains a significant limitation for patients 
undergoing percutaneous coronary intervention, with 30% to 
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Table 4. Angiographic Outcomes at Six-Month Follow-Up According to Intervention Assignment 
Atherectomy Angioplasty 
Estrogen Estrogen Estrogen Estrogen 
Users Nonusers p Users Nonusers p 
(n = 18) (n = 79) Value (n = 23) (n = 84) Value 
Late loss (mm)* 0.06 (-0.15, 0.29) -0.61 ( 0.99, -0.23) 0.0006 -0.29 (-0.82, 0.09) -0.39 (-0.66, -0.08) 0.77 
Late loss indext 0.06 (-0.20, 0.34) -0.63 (-0.97, -0.2l) 0.002 0.40 (-0.81, 0.17) -0.44 (-(I.84, -0.08) 0.40 
Minimal lumen diameter (mm) 1.63 (0.83, 1.99) 1.15 (0.88, 1.49) 0.044 1.26 (0.88, 1.53) 1.32 (0.92, 1.72) 0.34 
Rate of restenosis:}: 27% 57% 0.038 48% 50% 0.69 
Percent stenosis (%)§ 31 (2(/, 59) 59 (38, 69) 0.0l 51 (42, 66) 53 (44, 67) 0.78 
*Defined as postprocedure minimal lumen diameter minus 6-month follow-up minimal lumen diameter, tLate loss divided by acute gain in minimal lumen diameter. 
:~>50% stenosis after an initially successful procedure. §Actual percent stenosis. Data presented are median value (25th, 75th percentile) or percent of patient group. 
50% of patients experiencing reocclusion within 6 months 
(1-4). Unfortunately, clinical trials evaluating the efficacy of 
->20 pharmacologic agents have failed to demonstrate any 
significant success in modifying the rate of restenosis after 
balloon angioplasty (5-12). In contrast, our observational study 
revealed that the use of estrogen replacement therapy was 
associated with an overall reduction in late loss in target vessel 
lumen after percutaneous coronary intervention i  postmeno- 
pausal women. This beneficial effect of estrogen replacement 
therapy appears to be significantly greater in women undergo- 
ing directional coronary atherectomy than in those receiving 
conventional ngioplasty. 
Potential mechanism of action. Several potential mecha- 
nisms may account for the ability of estrogen to attenuate 
restenosis. Multiple observational studies and a recent ran- 
domized trial (30) demonstrated that estrogen alone and in 
combination with a progestin in postmenopausal women low- 
ers serum low density lipoprotein and increases high density 
lipoprotein levels. We also noted that women receiving estro- 
gen replacement therapy had significantly greater high density 
lipoprotein levels. This favorable modulation of lipoprotein 
metabolism therefore may provide a partial explanation for the 
lower angiographic measures of restenosis after percutaneous 
coronary intervention. However, available data on the effects 
of lovastatin (31), a more potent modifier of lipid profiles than 
estrogen, have failed to reveal any prevention of or reduction 
in restenosis. Likewise, significant differences between estro- 
gen users and nonusers persisted after we adjusted for differ- 
ences in high density lipoprotein levels. As a result, it seems 
improbable that the favorable lipoprotein effects of estrogen 
entirely account for the reduction in restenosis measures 
observed. 
Estrogen has also been shown (16-19) to have direct effects 
on the vasomotion of normal and atherosclerotic arteries 
through endothel ium-dependent and endothelium- 
independent mechanisms. Recent studies (20,21) have demon- 
strated that both short-term and long-term estrogen replace- 
ment therapy reverse the pathologic vasoconstriction bserved 
in atherosclerotic vessels. These findings demonstrate that 
estrogen may promote vasodilation i diseased coronary arter- 
ies and potentially reduce pathologic vasoconstriction after 
percutaneous coronary intervention. 
In addition, estrogen may prevent restenosis by altering 
cellular migration and neointimal proliferation after coronary 
intervention. After balloon-induced arterial injury, estrogen 
decreased platelet and neutrophil deposition at the site of 
injury (22). In vitro, physiologic levels of estrogen have been 
shown (23) to inhibit proliferation of vascular smooth muscle 
Figure 2. Cumulative frequency distribution of late loss in 
minimal umen diameter of the target lesion in estrogen 
users and nonusers undergoing angioplasty. 
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from the coronary arteries of female pigs. Several studies have 
evaluated the ability of estrogen to alter vascular esponses to 
injury in animal models. Although the results to date have 
been conflicting, the majority of studies (24-26) reported that 
estrogen significantly inhibited neointimal proliferation after 
arterial balloon injury. In contrast, a recent report by Geary 
and colleagues (27) concluded that estrogen did not inhibit 
balloon-induced proliferation of the intima in a nonhuman 
primate model. 
Device-specific response. The present study was the first to 
clinically evaluate the effect of estrogen replacement therapy 
on restenosis in humans. We found an overall beneficial 
association between the use of estrogen replacement therapy 
and a reduction i  late lumen loss after percutaneous coronary 
intervention. Although stratification by type of coronary inter- 
vention resulted in small subgroups (n = 97 and 107 for 
atherectomy and angioplasty, respectively), we found that 
estrogen replacement therapy was associated with a significant 
reduction in restenosis in patients who underwent atherec- 
Table 5. Clinical Outcomes atOne-Year Follow-Up 
Estrogen Estrogen 
Users Nonusers p 
(n = 47) (n = 196) Value 
Death 0 6 (3.0%) 0.24 
Myocardial infarction 3 (6.4%) 14 (6.9%) 0.94 
Coronary artery bypass urgery 3 (6.4%) 21 (10.3%) 0.44 
Need for nonsurgical coronary. 12 (25.5%) 58 (28.6%) 0.69 
intervention i  the target 
artery 
CCS class II, II] or IV* 5 (10.6%) 31 (21.3%) 0.29 
Composite clinical end pointt 15 (31.9%) 71 (35.5%) 0.75 
*Rates are based on proportion of patients with follow-up between 8 and 16 
months after randomization, tThe 1-year composite clinical end point was 
defined as death, myocardial infarction, coronary artery, bypass urgery, and 
nonsurgical coronary intervention in the target artery. Data presented are 
number of patients (rates by Kaplan-Meier survival analysis). CCS - Canadian 
Cardiovascular Society. 
tomy, whereas the effects were equivocal after conventional 
angioplasty. In fact, there was no significant loss in median 
lumen diameter among the 18 patients using estrogen who 
received atherectomy as compared with a 36% loss in minimal 
lumen diameter in those not receiving estrogen therapy. 
Among those who received balloon angioplasty, estrogen users 
and nonusers had similar late angiographic results (-0.29 vs. 
-0.39 mm late loss in minimal umen diameter, p = 0.77). 
These findings suggest that the effect of estrogen replace- 
ment therapy may be device specific. Such a device-specific 
response is also consistent with our current understanding of 
the pathophysiology of restenosis after coronary intervention. 
Although both neointimal hyperplasia nd late recoil have 
been implicated in restenosis, the former may have a signifi- 
cantly greater ole in restenosis after atherectomy than after 
conventional balloon angioplasty (32-34). Because previous in 
vitro and animal studies (23-26) have indicated that the 
presence of estrogen can reduce neointimal proliferation, our 
results demonstrating a reater impact of estrogen on resten- 
osis after atherectomy may support his mechanism of action. 
However, further evaluation is necessary as our study is the 
first to investigate arterial responses to estrogen after atherec- 
tomy injury. 
Limitations. This analysis was exploratory and several lim- 
itations need to be emphasized. Most important, the results are 
based on retrospective and nonrandomized data. Patients 
using estrogen replacement therapy differed from those not 
using estrogen. Although many differences in baseline charac- 
teristics between estrogen users and nonusers failed to reach 
statistical significance, the cumulative ffect may account for 
the variance in angiographic outcomes. Estrogen users under- 
going atherectomy were also significantly younger and had a 
greater family history of coronary artery disease than did 
nonusers. However, known potential confounding factors for 
restenosis were adjusted for in our primary end point analyses. 
Even after adjusting for diabetes, unstable angina and lesion 
location in the left anterior descending artery, the use of 
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estrogen replacement therapy remained the most significant 
factor predicting late loss. 
A second limitation was our limited overall sample size, 
particularly when we stratified the analyses by type of coronary 
intervention used. This limited sample size increases the 
possibility of a chance or spurious finding. However, our 
primary angiographic end point was prospectively defined and 
ascertained and the reviewer did not know the patient's 
estrogen status. Despite this, confirmation of these subgroup 
analyses in larger clinical data bases, when available, is indi- 
cated. 
The study's limited sample size also constrained our ability 
to demonstrate potentially significant differences in clinical 
outcomes between estrogen users and nonusers. Although 
estrogen users had slightly fewer deaths and myocardial infarc- 
tions and demonstrated a trend toward a lower rate of 
exertional angina at 1-year follow-up, the study was not 
adequately powered to detect differences in clinical outcome. 
Recent preliminary evidence from Kim and colleagues (35) 
suggests that estrogen replacement therapy may improve long- 
term survival after percutaneous interventions in postmeno- 
pausal women. 
Conclusions. This exploratory study suggests that estrogen 
replacement therapy in postmenopausal women may reduce 
restenosis after coronary intervention, particularly in patients 
receiving directional coronary atherectomy. Given the poten- 
tial clinical importance of these findings, the use of estrogen 
replacement therapy as a means of preventing restenosis after 
coronary intervention deserves further evaluation. 
We acknowledge the expert editorial and technical assistance ofPenny Hodgson, 
BA in preparation of the manuscript. 
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